Frontage Laboratories, Inc. has completed the expansion of its bioanalytical laboratories in Exton, PA, adding 10,000 sq.-ft. of lab space and enhancing bioanalytical capabilities in biologics and small molecule drug development, biomarkers, cell and gene therapy, and high-throughput clinical sample management. The expansion brings the total lab space at the Exton site to 80,000 sq.-ft.

In addition to sample management and increased lab space, the company also enhanced instrumentation, systems, robotics automation, software and personnel capacity. A center of excellence supporting cell and gene therapy has been established which includes dedicated laboratories in DNA/RNA sample preparation, PCR, flow cytometry, and cell culture. The expansion provides greater biomarker, PK, and immunogenicity bioanalytical capacity to support large Clinical Phase II-IV studies.

Dr. John Lin, Ph.D., EVP of Frontage’s Global Bioanalytical Services, “The expansion provides our clients with heightened biomarker and biologic services in a state-of-the-art facility to facilitate drug discovery and development.  It enables Frontage to provide the enhanced capability and capacity for the bioanalytical support of the gene and cell therapies and late phase clinical studies.”